fda warning letters compounded semaglutide telehealth 2024 2025 Last month, the issued 25 to companies over what it called false or misleading claims about GLP-1 medications. Read more at the link in the comments below FDA Drug Recalls and Warnings:

The growth of GLP-1 treatment within diabetes Glucagon-like peptide 1 (GLP-1) receptor agonists have taken the healthcare world by storm, becoming one of the most successful drug classes of all time, reaching an astonishing $110 billion in sales in 2024 alone 1

According to Kumar, she is taking the right actions

Those are surgical-range outcomes from a once-weekly injection

You can also calculate your waist-to-hip ratio

We stripped away the guesswork and replaced it with strict in-house protocols and verified data

The GLP-1 based peptides (semaglutide and tirzepatide) produce the most dramatic weight loss results but come with notable gastrointestinal side effects during titration